| |
| |
|
| Insider
Information: |
Bishop Hans Edgar |
| Relationship: |
Director |
| City: |
Seattle |
| State: |
WA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
10,734,769 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$15,679,829 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
10,734,769 |
|
|
| Total
Value |
$15,679,829 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Dendreon Corp |
DNDN |
Chief Operating Officer |
2011-07-29 |
151,189 |
2010-01-29 |
0 |
Premium* |
|
|
Avanir Pharmaceuticals |
AVNR |
Director |
2014-02-12 |
93,350 |
2013-02-14 |
0 |
Premium* |
|
|
Juno Therapeutics, Inc. |
JUNO |
CEO & President, Direc... |
2018-03-05 |
0 |
|
0 |
Premium* |
|
|
Agilent Technologies Inc |
A |
Director |
2024-03-15 |
24,976 |
2017-07-18 |
0 |
Premium* |
|
|
Celgene Corp |
CELG |
|
2019-11-20 |
0 |
2019-11-20 |
0 |
Premium* |
|
|
Sana Biotechnology, Inc. |
SANA |
|
2024-04-05 |
5,779,640 |
|
0 |
Premium* |
|
|
Lyell Immunopharma, Inc. |
LYEL |
Director |
2022-09-08 |
4,685,614 |
2021-06-21 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
62 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| A |
Agilent Technologies Inc |
Director |
• • – |
2017-07-18 |
4 |
A |
$61.21 |
$134,601 |
D/D |
2,199 |
2,199 |
0 |
- |
|
| A |
Agilent Technologies Inc |
Director |
• • – |
2018-03-22 |
4 |
A |
$67.47 |
$291,070 |
D/D |
4,314 |
6,522 |
0 |
- |
|
| A |
Agilent Technologies Inc |
Director |
• • – |
2019-03-21 |
4 |
A |
$82.00 |
$282,936 |
D/D |
3,450 |
10,032 |
0 |
- |
|
| A |
Agilent Technologies Inc |
Director |
• • – |
2020-04-17 |
4 |
A |
$73.01 |
$299,921 |
D/D |
4,108 |
14,228 |
0 |
- |
|
| A |
Agilent Technologies Inc |
Director |
• • – |
2020-08-03 |
4 |
A |
$93.91 |
$16,622 |
D/D |
177 |
14,456 |
0 |
- |
|
| A |
Agilent Technologies Inc |
Director |
• • – |
2021-03-18 |
4 |
A |
$121.59 |
$324,896 |
D/D |
2,672 |
17,176 |
0 |
- |
|
| A |
Agilent Technologies Inc |
Director |
• • – |
2022-03-17 |
4 |
A |
$136.82 |
$353,269 |
D/D |
2,582 |
19,853 |
0 |
- |
|
| A |
Agilent Technologies Inc |
Director |
– • – |
2023-03-16 |
4 |
A |
$136.82 |
$328,231 |
D/D |
2,399 |
22,379 |
0 |
- |
|
| A |
Agilent Technologies Inc |
Director |
• • – |
2024-03-15 |
4 |
A |
$147.48 |
$358,081 |
D/D |
2,428 |
24,976 |
0 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
Director |
– • – |
2013-02-14 |
4 |
A |
$0.00 |
$0 |
D/D |
19,450 |
64,450 |
0 |
- |
|
| AVNR |
Avanir Pharmaceuticals |
Director |
– • – |
2014-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
28,900 |
93,350 |
0 |
- |
|
| CELG |
Celgene Corp |
|
– • – |
2019-11-20 |
4 |
D |
$0.00 |
$0 |
D/D |
(23,088) |
0 |
0 |
- |
|
| DNDN |
Dendreon Corp |
Chief Operating Officer |
• – – |
2010-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
110,000 |
110,000 |
0 |
- |
|
| DNDN |
Dendreon Corp |
Chief Operating Officer |
• – – |
2010-12-07 |
4 |
A |
$0.00 |
$0 |
D/D |
27,000 |
137,000 |
0 |
- |
|
| DNDN |
Dendreon Corp |
Chief Operating Officer |
• – – |
2011-01-20 |
4 |
A |
$0.00 |
$0 |
D/D |
28,051 |
165,051 |
0 |
- |
|
| DNDN |
Dendreon Corp |
Chief Operating Officer |
• – – |
2011-02-10 |
4 |
D |
$35.01 |
$323,107 |
D/D |
(9,229) |
155,822 |
0 |
- |
|
| DNDN |
Dendreon Corp |
Chief Operating Officer |
• – – |
2011-04-29 |
4 |
D |
$42.27 |
$98,998 |
D/D |
(2,342) |
153,480 |
0 |
- |
|
| DNDN |
Dendreon Corp |
Chief Operating Officer |
• – – |
2011-07-29 |
4 |
D |
$37.65 |
$86,256 |
D/D |
(2,291) |
151,189 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
See RemarksOfficer |
• • – |
2014-12-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,724,859 |
|
- |
|
| JUNO |
Juno Therapeutics, Inc. |
CEO and President |
• • – |
2015-12-15 |
4 |
AS |
$44.77 |
$4,183,411 |
D/D |
(91,500) |
2,687,359 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
CEO and President |
• • – |
2015-12-15 |
4 |
OE |
$6.36 |
$343,440 |
D/D |
54,000 |
2,778,859 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
See Remarks |
• • – |
2016-02-29 |
4 |
AS |
$35.27 |
$3,205,005 |
D/D |
(90,750) |
2,650,609 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
See Remarks |
• • – |
2016-02-29 |
4 |
OE |
$6.36 |
$343,440 |
D/D |
54,000 |
2,741,359 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
CEO & President |
• • – |
2016-06-09 |
4 |
AS |
$45.80 |
$4,212,344 |
D/D |
(90,750) |
2,613,859 |
0 |
- |
|
| JUNO |
Juno Therapeutics, Inc. |
CEO & President |
• • – |
2016-06-09 |
4 |
OE |
$6.36 |
$343,440 |
D/D |
54,000 |
2,704,609 |
0 |
- |
|
62 Records found
|
|
Page 1 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
